Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Cancer Japan

Keryx surges as monitoring board backs Phase III colorectal perifosine study

This article was originally published in Scrip

Executive Summary

Keryx Biopharmaceuticals' shares rose on 31 August 2011 by 7.3%, to $4.07, on news that an independent monitoring board was recommending, following an interim analysis, that the Phase III perifosine X-PECT trial continue as planned until it is completed. The company licensed North American rights to the potential treatment for refractory colorectal cancer patients from Aeterna Zentaris.

Table

View full table

Topics

Related Companies

Tags:
Cancer Japan
Latest Headlines

Quick Listen: Scrip's Five Must-Know Things

Avistone Wins China Approval For First C-Met Inhibitor In Glioblastoma

Are Jubilant Pharmova’s US Plant Closure, FDA Observations At Canada Unit A Concern?

X4 Gets First Approval In Ultra-Rare Disorder, Needs Time To Build A Market

See All
UsernamePublicRestriction

Register

SC014281

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By